Predictive factors for response and progression after treatment with rituximab in previously untreated patients with Waldenstrom's macroglobulinemia (WM).

被引：0
|
作者：
Anagnostopoulos, A
Treon, SP
Zervas, K
Branagan, A
Gika, D
Zomas, A
Kyrtsonis, MC
Vassou, A
Anagnostopoulos, N
Pangalis, G
Dimopoulos, MA
机构：
[1] Greek Myeloma Study Grp, Dept Clin Therapeut, Athens, Greece
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3485
引用
收藏
页码：973A / 973A
页数：1
相关论文
共 50 条
  • [41] Ibrutinib plus rituximab for the treatment of adult patients with Waldenstrom's macroglobulinemia: a safety evaluation
    Migkou, Magdalini
    Fotiou, Despina
    Gavriatopoulou, Maria
    Dimopoulos, Meletios Athanasios
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (09) : 987 - 995
  • [42] Rituximab therapy in previously treated Waldenstrom's macroglobulinemia: Preliminary evidence of activity.
    Byrd, JC
    White, CA
    Link, B
    Thomas, S
    Valasquez, WS
    Rosenberg, J
    Grillo-Lopez, AJ
    BLOOD, 1998, 92 (10) : 106A - 106A
  • [43] Treatment and outcome of patients with Waldenstrom's Macroglobulinemia (WM) in private oncology practices and a university hospital
    Hensel, M.
    Brust, J.
    Ploeger, C.
    Schuster, D.
    Memmer, M.
    Hensel, L.
    Mosthaf, S.
    Franz-Werner, J.
    Feustel, H-P
    Mosthaf, F.
    Witzens-Harig, M.
    ONKOLOGIE, 2011, 34 : 268 - 268
  • [44] A case of Waldenstrom macroglobulinemia with severe systemic myalgia after rituximab treatment
    Fujii, Soichiro
    Takeuchi, Makoto
    Kondou, Kaho
    Matsumura, Akihumi
    ANNALS OF ONCOLOGY, 2021, 32 : S356 - S356
  • [45] The unfolded protein response is a determinant of disease actvity in Waldenstrom's Macroglobulinemia (WM)
    Leleu, X
    Xu, L
    Santos, DD
    Ho, AW
    Hunter, ZR
    O'Connor, K
    Manning, RJ
    Tournilhac, O
    Chemaly, M
    Branagan, AR
    Patterson, CJ
    Anderson, KC
    Treon, S
    BLOOD, 2005, 106 (11) : 292A - 292A
  • [46] Deepening of Response after Completing Rituximab-Containing Primary Therapy in Patients with Waldenstrom Macroglobulinemia
    Castillo, Jorge J.
    Gustine, Joshua
    Dubeau, Toni
    Meid, Kirsten
    Keezer, Andrew
    Xu, Lian
    Yang, Guang
    Hunter, Zachary R.
    Treon, Steven P.
    BLOOD, 2018, 132
  • [47] Paradoxical increases in serum IgM levels and serum viscosity following rituximab therapy in patients with Waldenstrom's macroglobulinemia (WM).
    Treon, SP
    Branagan, AR
    Anderson, KC
    BLOOD, 2003, 102 (11) : 690A - 690A
  • [48] Improvement of the thermal amplitude after rituximab treatment for cold agglutinin disease with Waldenstrom's macroglobulinemia
    Hattori, Norimichi
    Ishii, Noriko
    Ariizumi, Hirotsugu
    Adachi, Daisuke
    Matsuda, Isao
    Nakamaki, Tsuyoshi
    Tomoyasu, Shigeru
    ANNALS OF HEMATOLOGY, 2010, 89 (01) : 103 - 104
  • [49] Myelopathy from Waldenstrom's macroglobulinemia: improvement after Rituximab therapy
    Liberato, B
    Riethmuller, A
    Comenzo, RL
    Lis, E
    Raizer, JJ
    JOURNAL OF NEURO-ONCOLOGY, 2003, 63 (02) : 207 - 211
  • [50] Rituximab and Fludarabine or Cyclophosphamide Combination Treatment for Older Waldenstrom Macroglobulinemia Patients
    Xu, XiaoWei
    Wang, Chun
    Wang, YaMin
    Zhou, LiLi
    Bai, HaiTao
    TURKISH JOURNAL OF HEMATOLOGY, 2013, 30 (04) : 422 - 423
12345